Cargando…

Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease

OBJECTIVE: This study aimed to investigate the clinical significance of Krebs von den Lungen‐6 (KL‐6) serum levels in patients with anti‐MDA5 antibody‐positive dermatomyositis (anti‐MDA5(+) DM) having interstitial lung disease (ILD), especially in the amyopathic DM phenotype. METHODS: The serum KL‐6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yan, Fu, Qiong, Wang, Ran, Guo, Qiang, Bao, Chunde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805307/ https://www.ncbi.nlm.nih.gov/pubmed/31301087 http://dx.doi.org/10.1002/jcla.22978

Ejemplares similares

Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease
por: Ren, Fang-Ping, et al.
Publicado: (2023)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report
por: Mihailescu, Maria L., et al.
Publicado: (2021)

Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema
por: Chen, Lauren, et al.
Publicado: (2020)

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
por: Aissaoui, Houari, et al.
Publicado: (2021)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis
por: Wongjirattikarn, Rachot, et al.
Publicado: (2020)

Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
por: Kawamoto, Shinya, et al.
Publicado: (2021)

Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis
por: Li, Liubing, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis
por: Liu, Tao, et al.
Publicado: (2022)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Correlation between CT Score and KL-6: A Severity Assessing in Juvenile Dermatomyositis Associated Interstitial Lung Disease
por: Wang, Chi, et al.
Publicado: (2023)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

Intramuscular lesions in musculoskeletal MRI as a favourable prognostic sign in patients with anti-MDA5 antibody-positive dermatomyositis
por: Oto, Yohsuke, et al.
Publicado: (2023)

Anti-MDA5 Positive Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease and Correlation between Serum Ferritin Level and Treatment Response
por: Zohar, Daniela Noa, et al.
Publicado: (2020)

Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study
por: Huang, Linlin, et al.
Publicado: (2021)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center
por: Huang, Linlin, et al.
Publicado: (2021)

Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications
por: Ye, Yan, et al.
Publicado: (2022)

A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients
por: Qian, Jinjing, et al.
Publicado: (2023)

Cutaneous Features of Anti-MDA-5 Antibody-Positive Amyopathic Dermatomyositis in a Sudanese Patient
por: Alqahtani, Nouf, et al.
Publicado: (2021)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level
por: Osawa, Takeshi, et al.
Publicado: (2017)

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports
por: Takahashi, Rina, et al.
Publicado: (2021)

Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease
por: Li, Yan, et al.
Publicado: (2023)

Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review
por: Lu, Ci, et al.
Publicado: (2023)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Subcutaneous Calcinosis in a Patient with Anti-MDA5 Positive Dermatomyositis
por: Hou, Ruihong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e62i38v25tdd0m6ptcv8hipgaj